

Date: 11 April 2022

Re: Freedom of Information Request
Ref: 83-2022

Thank you for your email dated the 15/3/2022, requesting information in relation to gastric and oesophageal cancer.

The information that you require is as follows:

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) **11**
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) **0**
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **1**
- Any other systemic anti-cancer therapy **43**
- Palliative care only **0**

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **0**
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) **0**
- Nivolumab monotherapy **1**
- Nivolumab and Ipilimumab **0**
- Any other systemic anti-cancer therapy **8**
- Palliative care only **0**

Q3. Of the Oesophageal Cancer patients (from Q2) treated with Pembrolizumab in the past 3 months, how many patients were treated for:

- Oesophageal adenocarcinoma **0**
- Oesophageal squamous cell carcinoma **0**

Q4. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) **0**
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) **0**
- Nivolumab monotherapy **1**
- Nivolumab and Ipilimumab **0**
- Any other systemic anti-cancer therapy **0**
- Palliative care only **1**

Q5. Of the advanced/metastatic oesophageal cancer patients (from Q4) treated in the past 3 months, how many patients were treated for:

- Advanced/metastatic oesophageal adenocarcinoma **1**
- Advanced/metastatic oesophageal squamous cell carcinoma **1**

Q6. Does your trust participate in any active clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Open to Recruitment

Project Acronym	Project Full title	Project phase	Project site date open to recruitment	Recruited	Project site actual recruitment end date
SCOPE-2	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	Phase II/III	28/09/2018	20	

Closed to Recruitment – In follow-up

Project Acronym	Project Full title	Project phase	Project site date open to recruitment	Recruited	Project site actual recruitment end date
RAINFALL	NCRN3464 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)	Phase III	23/10/2015	8	18/08/2016
CYTOFLOC	Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study	Not Applicable	17/12/2018	6	31/01/2020
NEOSCOPE	A randomised Phase II study of two preoperative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.	Phase II	21/08/2014	2	09/02/2015

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

The Information Governance Team
Contact Email: ccf-tr.foi@nhs.net